JP2025511409A5 - - Google Patents
Info
- Publication number
- JP2025511409A5 JP2025511409A5 JP2024559046A JP2024559046A JP2025511409A5 JP 2025511409 A5 JP2025511409 A5 JP 2025511409A5 JP 2024559046 A JP2024559046 A JP 2024559046A JP 2024559046 A JP2024559046 A JP 2024559046A JP 2025511409 A5 JP2025511409 A5 JP 2025511409A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- sequence described
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2204927.4 | 2022-04-04 | ||
| GBGB2204927.4A GB202204927D0 (en) | 2022-04-04 | 2022-04-04 | Cells expressing mesothelin |
| US202363482752P | 2023-02-01 | 2023-02-01 | |
| US63/482,752 | 2023-02-01 | ||
| PCT/IB2023/053431 WO2023194911A1 (en) | 2022-04-04 | 2023-04-04 | Cells expressing an anti-mesothelin car |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025511409A JP2025511409A (ja) | 2025-04-15 |
| JP2025511409A5 true JP2025511409A5 (enExample) | 2026-04-14 |
Family
ID=86328908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559046A Pending JP2025511409A (ja) | 2022-04-04 | 2023-04-04 | 抗メソテリンｃａｒを発現する細胞 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250025555A1 (enExample) |
| EP (2) | EP4628504A3 (enExample) |
| JP (1) | JP2025511409A (enExample) |
| KR (1) | KR20240168982A (enExample) |
| CN (1) | CN119110845A (enExample) |
| AU (1) | AU2023250251A1 (enExample) |
| CA (1) | CA3254719A1 (enExample) |
| CL (2) | CL2024002948A1 (enExample) |
| CO (1) | CO2024013343A2 (enExample) |
| IL (1) | IL315660A (enExample) |
| MX (1) | MX2024012314A (enExample) |
| PE (1) | PE20242282A1 (enExample) |
| TW (1) | TW202405164A (enExample) |
| WO (1) | WO2023194911A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20242341A1 (es) | 2022-04-04 | 2024-12-12 | Gammadelta Therapeutics Ltd | Blindaje genetico novedoso |
| WO2025240496A1 (en) * | 2024-05-14 | 2025-11-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors |
| WO2026069206A1 (en) * | 2024-09-25 | 2026-04-02 | Takeda Pharmaceutical Company Limited | Hypoimmunogenic modified gamma delta t cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| US9272002B2 (en) * | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EP3822342A4 (en) * | 2018-07-13 | 2022-08-03 | Kyoto University | METHOD OF PRODUCTION OF GAMMA DELTA T-CELLS |
| US20220088074A1 (en) * | 2019-02-21 | 2022-03-24 | Regents Of The University Of Minnesota | Genetically modified gamma delta t cells and methods of making and using |
| WO2021207290A1 (en) * | 2020-04-06 | 2021-10-14 | Synthekine, Inc. | Engineered immune cells |
| WO2021259237A1 (en) * | 2020-06-22 | 2021-12-30 | Nanjing Legend Biotech Co., Ltd. | GENETIC ENGINEERING OF γδ T CELLS FOR IMMUNOTHERAPY |
| KR102309543B1 (ko) * | 2020-08-04 | 2021-10-07 | 주식회사 셀렌진 | 메소텔린에 특이적으로 결합하는 항-메소텔린 키메릭 항원 수용체 |
| EP4208176A4 (en) * | 2020-09-04 | 2025-06-25 | Gavish-Galilee Bio Applications Ltd. | Constructs of the bicistronic inhibiting chimeric antigen receptor (ICAR)/activating chimeric antigen receptor (ACAR) for use in cancer therapies |
| GB202013962D0 (en) * | 2020-09-04 | 2020-10-21 | Gammadelta Therapeutics Ltd | Immunotherapy composition |
-
2023
- 2023-04-04 EP EP25175873.6A patent/EP4628504A3/en active Pending
- 2023-04-04 KR KR1020247032909A patent/KR20240168982A/ko active Pending
- 2023-04-04 CN CN202380032086.3A patent/CN119110845A/zh active Pending
- 2023-04-04 IL IL315660A patent/IL315660A/en unknown
- 2023-04-04 JP JP2024559046A patent/JP2025511409A/ja active Pending
- 2023-04-04 AU AU2023250251A patent/AU2023250251A1/en active Pending
- 2023-04-04 CA CA3254719A patent/CA3254719A1/en active Pending
- 2023-04-04 WO PCT/IB2023/053431 patent/WO2023194911A1/en not_active Ceased
- 2023-04-04 PE PE2024002150A patent/PE20242282A1/es unknown
- 2023-04-04 EP EP23721778.1A patent/EP4504344A1/en active Pending
- 2023-04-06 TW TW112112882A patent/TW202405164A/zh unknown
-
2024
- 2024-09-30 CO CONC2024/0013343A patent/CO2024013343A2/es unknown
- 2024-10-01 CL CL2024002948A patent/CL2024002948A1/es unknown
- 2024-10-03 MX MX2024012314A patent/MX2024012314A/es unknown
- 2024-10-04 US US18/906,842 patent/US20250025555A1/en not_active Abandoned
-
2025
- 2025-07-25 CL CL2025002218A patent/CL2025002218A1/es unknown